Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
By Elana Gotkine HealthDay Reporter
.jpg?width=1200)
MONDAY, May 12, 2025 -- The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according to a study published online May 12 in Cancer.
Noting that adding bevacizumab to 1L chemotherapy for stage III/IV epithelial ovarian cancer significantly improved progression‐free survival in clinical trials, Linda R. Duska, M.D., M.P.H., from the University of Virginia School of Medicine in Charlottesville, and colleagues examined an electronic health record-derived database for outcomes in patients with stage III/IV epithelial ovarian cancer who initiated 1L chemotherapy ± bevacizumab. The median real‐world time to next treatment and real‐world overall survival were estimated.
The analyses included 1,752 patients, with a median follow-up of 18.5 months. The researchers found that for patients with high-risk prognostic factors (stage IV disease or stage III disease with either visible residual disease or no documentation of surgery), real-world time to next treatment was significantly longer with 1L chemotherapy plus bevacizumab versus chemotherapy alone (13.6 versus 11.7 months). Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival (31.1 versus 27.4 months). Real-world outcomes did not differ with the addition of bevacizumab for patients without high-risk prognostic factors.
"Results suggested that the real‐world benefit of adding bevacizumab to a 1L chemotherapy regimen was limited to patients with high‐risk prognostic factors, defined as stage IV disease, stage III disease with visible residual disease, or stage III disease with no evidence of surgery," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including GSK, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
New Model Developed for Identifying DVT in Epithelial Ovarian Cancer
TUESDAY, June 17, 2025 -- A model with eight independent risk factors can predict the risk for deep vein thrombosis (DVT) in patients with epithelial ovarian cancer (EOC)...
American College of Obstetricians and Gynecologists, May 16-18
The annual meeting of the American College of Obstetricians and Gynecologists (ACOG) was held from May 16 to 18 in Minneapolis and was attended by more than 4,000...
Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer
TUESDAY, May 13, 2025 -- For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.